2,288
Views
35
CrossRef citations to date
0
Altmetric
Reviews

Practical review of immunizations in adult patients with cancer

&
Pages 2606-2614 | Received 16 Apr 2015, Accepted 10 Jun 2015, Published online: 16 Sep 2015

References

  • Meisel R, Toschke AM, Heiligensetzer C, Dilloo D, Laws HJ, von Kries R. Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia. Br J Haematol 2007; 137:457-60; PMID:17488489; http://dx.doi.org/10.1111/j.1365-2141.2007.06601.x
  • Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ, Group S. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect 2010; 138:1804-10; PMID:20429967; http://dx.doi.org/10.1017/S0950268810000919
  • Chemaly RF, Vigil KJ, Saad M, Vilar-Compte D, Cornejo-Juarez P, Perez-Jimenez C, Mubarak S, Salhab M, Jiang Y, Granwehr B, et al. A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes. Cancer 2012; 118:4627-33; PMID:22359314; http://dx.doi.org/10.1002/cncr.27447
  • Kwon HJ, Lee JW, Chung NG, Cho B, Kim HK, Kang JH. Assessment of serologic immunity to diphtheria-tetanus-pertussis after treatment of Korean pediatric hematology and oncology patients. J Korean Med Sci 2012; 27:78-83; PMID:22219618; http://dx.doi.org/10.3346/jkms.2012.27.1.78
  • Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:309-18; PMID:24421306; http://dx.doi.org/10.1093/cid/cit816
  • Ljungman P. Vaccination of immunocompromised patients. Clin Microbiol Infect 2012; 18(Suppl 5):93-9; PMID:23051059; http://dx.doi.org/10.1111/j.1469-0691.2012.03971.x
  • Berglund A, Willen L, Grodeberg L, Skattum L, Hagberg H, Pauksens K. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Incol 2014; 53:1212-20; PMID:24865118; http://dx.doi.org/10.3109/0284186X.2014.914243
  • Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Different 2014; 21:15-25; PMID:23787994; http://dx.doi.org/10.1038/cdd.2013.67
  • Schwarzberg AB, Stover EH, Sengupta T, Michelini A, Vincitore M, Baden LR, Kulke MH. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest 2007; 25:249-55; PMID:17612935; http://dx.doi.org/10.1080/07357900701206380
  • Kotton CN, Poznansky MC. Vaccination of oncology patients: an effective tool and an opportunity not to be missed. Oncologist 2012; 17:1-2; PMID:22240542; http://dx.doi.org/10.1634/theoncologist.2011-0383
  • Balmer P, Cant AJ, Borrow R. Anti-pneumococcal antibody titre measurement: what useful information does it yield? J Clin Pathol 2007; 60:345-50; PMID:16950855; http://dx.doi.org/10.1136/jcp.2006.041210
  • Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 1997; 102:2-9; discussion 25–6; PMID:10868136; http://dx.doi.org/10.1016/S0002-9343(97)00003-X
  • Schepetiuk S, Papanaoum K, Qiao M. Spread of influenza A virus infection in hospitalised patients with cancer. Aust N Z J Med 1998; 28:475-6; PMID:9777122; http://dx.doi.org/10.1111/j.1445-5994.1998.tb02089.x
  • Advisory Committee on Immunization P. Prevention and control of influenza with vaccines: interim recommendations of the advisory committee on immunization practices (ACIP), 2013. MMWR Morb Mortal Wkly Rep 2013; 62:356; PMID:23657110
  • Carr S, Allison KJ, Van De Velde LA, Zhang K, English EY, Iverson A, Daw NC, Howard SC, Navid F, Rodriguez-Galindo C, et al. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis 2011; 204:1475-82; PMID:21949042; http://dx.doi.org/10.1093/infdis/jir561
  • Matsuzaki A, Suminoe A, Koga Y, Kinukawa N, Kusuhara K, Hara T. Immune response after influenza vaccination in children with cancer. Pediatr Blood Cancer 2005; 45:831-7; PMID:16007602; http://dx.doi.org/10.1002/pbc.20470
  • Pauksen K, Linde A, Hammarstrom V, Sjolin J, Carneskog J, Jonsson G, Oberga G, Engelmann H, Ljungman P. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis 2000; 30:342-8; PMID:10671339; http://dx.doi.org/10.1086/313663
  • Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-96; PMID:17544181; http://dx.doi.org/10.1016/j.vaccine.2007.03.046
  • Brydak LB, Guzy J, Starzyk J, Machala M, Gozdz SS. Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 2001; 9:65-8; PMID:11147146; http://dx.doi.org/10.1007/s005200000186
  • Meerveld-Eggink A, de Weerdt O, van der Velden AM, Los M, van der Velden AW, Stouthard JM, Nijziel MR, Westerman M, Beeker A, van Beek R, et al. Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol 2011; 22:2031-5; PMID:21303799; http://dx.doi.org/10.1093/annonc/mdq728
  • Anderson H, Petrie K, Berrisford C, Charlett A, Thatcher N, Zambon M. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer 1999; 80:219-20; PMID:10389999; http://dx.doi.org/10.1038/sj.bjc.6690342
  • Goossen GM, Kremer LC, van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006484. http://dx.doi.org/10.1002/14651858.CD006484.pub2
  • Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, Zambon M, Scarffe JH. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 2000; 82:1261-5; PMID:10755398; http://dx.doi.org/10.1054/bjoc.1999.1088
  • Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, et al. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 2006; 194:1394-7; PMID:17054068; http://dx.doi.org/10.1086/508493
  • Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, Sigurdardottir B, Hoeper A, Graham IL, Edelman R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25:7656-63; PMID:17913310; http://dx.doi.org/10.1016/j.vaccine.2007.08.042
  • Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis 1993; 12:778-82; PMID:8307050; http://dx.doi.org/10.1007/BF02098469
  • Cheng FW, Chan PK, Leung WK, Lee V, Shing MK, Yeung AC, Li CK. Pandemic (H1N1) 2009 vaccine in paediatric oncology patients: one dose or two doses? Br J Haematol 2011; 154:408-9; PMID:21488856; http://dx.doi.org/10.1111/j.1365-2141.2010.08501.x
  • Centers for Disease C, Prevention. Influenza vaccination coverage among children aged 6 months–18 years - eight immunization information system sentinel sites, United States, 2008-09 influenza season. MMWR Morb Mortal Wkly Rep 2009; 58:1059-62; PMID:19798018
  • Pabst LJ, Chaves SS, Weinbaum C. Trends in compliance with two-dose influenza vaccine recommendations among children aged 6 months through 8 years. Vaccine 2013; 31:3116-20; PMID:23684827; http://dx.doi.org/10.1016/j.vaccine.2013.04.080
  • Cheuk DK, Chiang AK, Lee TL, Chan GC, Ha SY. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD006505. http://dx.doi.org/10.1002/14651858.CD006505.pub2.
  • Lipsky BA, Boyko EJ, Inui TS, Koepsell TD. Risk factors for acquiring pneumococcal infections. Arch Intern Med 1986; 146:2179-85; PMID:3778047; http://dx.doi.org/10.1001/archinte.1986.00360230105016
  • Itala M, Helenius H, Nikoskelainen J, Remes K. Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur J Haematol 1992; 48:266-70; PMID:1644158; http://dx.doi.org/10.1111/j.1600-0609.1992.tb01805.x
  • Centers for Disease C, Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mort Wkly Rep 2012; 61:816-9; PMID:23051612
  • French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, Mwaiponya M, Zijlstra EE, Molyneux ME, Gilks CF. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-22; PMID:20200385; http://dx.doi.org/10.1056/NEJMoa0903029
  • Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577-84; PMID:23688526; http://dx.doi.org/10.1016/j.vaccine.2013.04.085
  • Hinge M, Ingels HA, Slotved HC, Molle I. Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma. APMIS 2012; 120:935-40; PMID:23009118; http://dx.doi.org/10.1111/j.1600-0463.2012.02922.x
  • Sinisalo M, Vilpo J, Itala M, Vakevainen M, Taurio J, Aittoniemi J. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine 2007; 26:82-7; PMID:18053620; http://dx.doi.org/10.1016/j.vaccine.2007.10.053
  • Chan CY, Molrine DC, George S, Tarbell NJ, Mauch P, Diller L, Shamberger RC, Phillips NR, Goorin A, Ambrosino DM. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996; 173:256-8; PMID:8537671; http://dx.doi.org/10.1093/infdis/173.1.256
  • Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine 2014; 32:2364-74; PMID:24606865; http://dx.doi.org/10.1016/j.vaccine.2014.02.002
  • Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIVinfected adults previously vaccinated with pneumococcal polysaccharide vaccine. J Infect Dis 2015 Jul 1; 212(1):18-27
  • Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9:213-20; PMID:19214194; http://dx.doi.org/10.1038/nri2494
  • Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114-25; PMID:25785969; http://dx.doi.org/10.1056/NEJMoa1408544
  • Florax A, Ehlert K, Becker K, Vormoor J, Groll AH. Bordetella pertussis respiratory infection following hematopoietic stem cell transplantation: time for universal vaccination? Bone Marrow Transplant 2006; 38:639-40; PMID:16964268; http://dx.doi.org/10.1038/sj.bmt.1705495
  • Senturk E, Sen S, Telli M. Empyema due to Bordetella pertussis in an adult patient with lung cancer. Arch De Bronconeumol 2012; 48:263-4; PMID:22503592; http://dx.doi.org/10.1016/j.arbr.2012.04.002
  • Winter K, Glaser C, Watt J, Harriman K, Centers for Disease C, Prevention. Pertussis epidemic–California, 2014. MMWR Morb Mort Wkly Rep 2014; 63:1129-32; PMID:25474033
  • Hammarstrom V, Pauksen K, Bjorkstrand B, Simonsson B, Oberg G, Ljungman P. Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients. Bone Marrow Transplant 1998; 22:67-71; PMID:9678798; http://dx.doi.org/10.1038/sj.bmt.1701289
  • Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012; 9:156-66; PMID:22271089; http://dx.doi.org/10.1038/nrclinonc.2012.1
  • Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100:182-8; PMID:1983820
  • Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62:299-307; PMID:11055239; http://dx.doi.org/10.1002/1096-9071(200011)62:3%3c299::AID-JMV1%3e3.0.CO;2-0
  • Zignol M, Peracchi M, Tridello G, Pillon M, Fregonese F, D'Elia R, Zanesco L, Cesaro S. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 2004; 101:635-41; PMID:15274078; http://dx.doi.org/10.1002/cncr.20384
  • Idilman R, Arat M. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. Exp Rev Anti-Infect Ther 2011; 9:641-52; PMID:21819330; http://dx.doi.org/10.1586/eri.11.79
  • Weitberg AB, Weitzman SA, Watkins E, Hinkle C, O'Rourke S, Dienstag JL. Immunogenicity of hepatitis B vaccine in oncology patients receiving chemotherapy. J Clin Oncol 1985; 3:718-22; PMID:3158725
  • Centers for Disease C, Prevention. Recommendation of the advisory committee on immunization practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mort Wkly Rep 2011; 60:1391-2; PMID:21993344
  • Coleman CN, McDougall IR, Dailey MO, Ager P, Bush S, Kaplan HS. Functional hyposplenia after splenic irradiation for Hodgkin's disease. Ann Intern Med 1982; 96:44-7; PMID:7053701; http://dx.doi.org/10.7326/0003-4819-96-1-44
  • Yu JW, Borkowski A, Danzig L, Reiter S, Kavan P, Mazer BD. Immune response to conjugated meningococcal C vaccine in pediatric oncology patients. Pediatr Blood Cancer 2007; 49:918-23; PMID:17366523; http://dx.doi.org/10.1002/pbc.21174
  • Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA Jr, Unger ER; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2014; 63:1-30; PMID:25167164
  • Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA, 3rd, Read JS, Handelsman EL, Nowak B, Sattler CA, Saah A, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defici Syndr 2010; 55:197-204; PMID:20574412; http://dx.doi.org/10.1097/QAI.0b013e3181de8d26
  • Gardner P, Eickhoff T, Poland GA, Gross P, Griffin M, LaForce FM, Schaffner W, Strikas R. Adult immunizations. Ann Intern Med 1996; 124:35-40; PMID:7503476; http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00007
  • Mutsch M, Spicher VM, Gut C, Steffen R. Hepatitis A virus infections in travelers, 1988-2004. Clin Infect Dis 2006; 42:490-7; PMID:16421793; http://dx.doi.org/10.1086/499816
  • Gunther M, Stark K, Neuhaus R, Reinke P, Schroder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 2001; 71:477-9; PMID:11233913; http://dx.doi.org/10.1097/00007890-200102150-00023
  • Morales-Castillo ME, Alvarez-Munoz MT, Solorzano-Santos F, Gonzalez-Robledo R, Jasso-Gutierrez L, Munoz-Hernandez O. Live varicella vaccine in both immunocompromised and healthy children. Arch Med Res 2000; 31:85-7; PMID:10767486; http://dx.doi.org/10.1016/S0188-4409(99)00080-6
  • Leung TF, Li CK, Hung EC, Chan PK, Mo CW, Wong RP, Chik KW. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers. Eur J Haematol 2004; 72:353-7; PMID:15059071; http://dx.doi.org/10.1111/j.1600-0609.2004.00216.x
  • Caniza MA, Hunger SP, Schrauder A, Valsecchi MG, Pui CH, Masera G, Members of International Study Group of Childhood ALL ( “Ponte di Legno Working Group”). The controversy of varicella vaccination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 58:12-6; PMID:20848637; http://dx.doi.org/10.1002/pbc.22759
  • Bhalla P, Forrest GN, Gershon M, Zhou Y, Chen J, LaRussa P, Steinberg S, Gershon AA. Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation. Clin Infect Dis 2015; 60:1068-74; PMID:25452596
  • Tseng HF, Tartof S, Harpaz R, Luo Y, Sy LS, Hetcher RC, Jacobsen SJ. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis 2014; 59:913-9; PMID:25097079; http://dx.doi.org/10.1093/cid/ciu498
  • Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices Centers for Disease C, Prevention. Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2008; 57:1-30; quiz CE2-4; PMID:18528318
  • Kernahan J, McQuillin J, Craft AW. Measles in children who have malignant disease. Br Med J 1987; 295:15-8; PMID:3113596; http://dx.doi.org/10.1136/bmj.295.6589.15
  • Mustafa MM, Weitman SD, Winick NJ, Bellini WJ, Timmons CF, Siegel JD. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infect Dis 1993; 16:654-60; PMID:8323578; http://dx.doi.org/10.1093/clind/16.5.654
  • Gray MM, Hann IM, Glass S, Eden OB, Jones PM, Stevens RF. Mortality and morbidity caused by measles in children with malignant disease attending four major treatment centres: a retrospective review. Br Med J 1987; 295:19-22; PMID:3113597; http://dx.doi.org/10.1136/bmj.295.6589.19
  • Feldman S, Andrew M, Norris M, McIntyre B, Iyer R. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia. Clin Infect Dis 1998; 27:388-90; PMID:9709893; http://dx.doi.org/10.1086/514661
  • McCarthy M. Measles cases exceed 100 in US outbreak. Bmj 2015; 350:h622; PMID:25646696; http://dx.doi.org/10.1136/bmj.h622
  • Patel SR, Ortin M, Cohen BJ, Borrow R, Irving D, Sheldon J, Heath PT. Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis 2007; 44:635-42; PMID:17278052; http://dx.doi.org/10.1086/511636
  • Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet 2011; 378:86-97; PMID:21474172; http://dx.doi.org/10.1016/S0140-6736(10)61493-6
  • Edgren G, Almqvist R, Hartman M, Utter GH. Splenectomy and the risk of sepsis: a population-based cohort study. Ann Surg 2014; 260:1081-7; PMID:24374533; http://dx.doi.org/10.1097/SLA.0000000000000439
  • Kuchar E, Nitsch-Osuch A, Stolarczyk C, Kurpas D, Zycinska K, Wardyn K, Szenborn L. Immunization coverage against capsular bacteria in splenectomized patients. Adv Exp Med Biol 2013; 788:139-45; PMID:23835971; http://dx.doi.org/10.1007/978-94-007-6627-3_21
  • Rosado MM, Gesualdo F, Marcellini V, Di Sabatino A, Corazza GR, Smacchia MP, Nobili B, Baronci C, Russo L, Rossi F, et al. Preserved antibody levels and loss of memory B cells against pneumococcus and tetanus after splenectomy: tailoring better vaccination strategies. Eur J Immunol 2013; 43:2659-70; PMID:23813052; http://dx.doi.org/10.1002/eji.201343577
  • Kim DK, Bridges CB, Harriman KH, Advisory Committee on Immunization P. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2015*. Ann Intern Med 2015; 162:214-23; http://dx.doi.org/10.7326/M14-2755
  • Balmer P, Falconer M, McDonald P, Andrews N, Fuller E, Riley C, Kaczmarski E, Borrow R. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun 2004; 72:332-7; PMID:14688112; http://dx.doi.org/10.1128/IAI.72.1.332-337.2004
  • Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2013; 62:1-28; PMID:23515099
  • Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. Jama 2008; 299:173-84; PMID:18182599; http://dx.doi.org/10.1001/jama.2007.29-c
  • Borrow R, Joseph H, Andrews N, Acuna M, Longworth E, Martin S, Peake N, Rahim R, Richmond P, Kaczmarski E, et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine 2000; 19:1129-32; PMID:11137248; http://dx.doi.org/10.1016/S0264-410X(00)00317-0
  • Kristensen K. Antibody response to a Haemophilus influenzae type b polysaccharide tetanus toxoid conjugate vaccine in splenectomized children and adolescents. Scand J Infect Dis 1992; 24:629-32; PMID:1465581; http://dx.doi.org/10.3109/00365549209054649
  • Cimaz R, Mensi C, D'Angelo E, Fantola E, Milone V, Biasio LR, Carnelli V, Zanetti AR. Safety and immunogenicity of a conjugate vaccine against Haemophilus influenzae type b in splenectomized and nonsplenectomized patients with Cooley anemia. J Infect Dis 2001; 183:1819-21; PMID:11372038; http://dx.doi.org/10.1086/320727
  • Askling HH, Dalm VA. The medically immunocompromised adult traveler and pre-travel counseling: status quo 2014. Travel Med Infect Dis 2014; 12:219-28; PMID:24821082; http://dx.doi.org/10.1016/j.tmaid.2014.04.009
  • Kotton CN. Travel and transplantation: travel-related diseases in transplant recipients. Curr Opin Organ Transplant 2012; 17:594-600; PMID:23147910
  • Yee SS, Dutta PR, Solin LJ, Vapiwala N, Kao GD. Lack of compliance with national vaccination guidelines in oncology patients receiving radiation therapy. J Support Oncol 2010; 8:28-34; PMID:20235421; http://dx.doi.org/10.1016/j.suponc.2010.10.005
  • Adriani KS, Brouwer MC, van der Ende A, van de Beek D. Bacterial meningitis in adults after splenectomy and hyposplenic states. Mayo Clin Proc 2013; 88:571-8; PMID:23628588; http://dx.doi.org/10.1016/j.mayocp.2013.02.009
  • Lammers AJ, Veninga D, Lombarts MJ, Hoekstra JB, Speelman P. Management of post-splenectomy patients in the Netherlands. Eur J Clin Microbiol Infect Dis 2010; 29:399-405; PMID:20094896; http://dx.doi.org/10.1007/s10096-009-0870-x

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.